Driehaus Capital Management LLC Crinetics Pharmaceuticals, Inc. Transaction History

Driehaus Capital Management LLC

$10.3 Billion
Q4 2024

A detailed history of Driehaus Capital Management LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Driehaus Capital Management LLC holds 6,141,014 shares of CRNX stock, worth $226 Million. This represents 3.06% of its overall portfolio holdings.

Number of Shares

6,141,014

Previous 5,885,248 4.35%

Holding current value

$226 Million

Previous $301 Million 4.45%

% of portfolio

3.06%

Previous 2.95%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$50.66 - $60.69 $13 Million - $15.5 Million	255,766 Added 4.35%	6,141,014 $314 Million
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $9.95 Million - $12.5 Million	-226,925 Reduced 3.71%	5,885,248 $301 Million
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $37.3 Million - $46 Million	885,876 Added 16.95%	6,112,173 $274 Million
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $6.48 Million - $8.72 Million	186,340 Added 3.7%	5,226,297 $245 Million
Q4 2023 Feb 14, 2024	SELL	$25.62 - $37.07 $2.37 Million - $3.42 Million	-92,330 Reduced 1.8%	5,039,957 $179 Million
Q3 2023 Nov 14, 2023	SELL	$15.97 - $30.59 $2.65 Million - $5.07 Million	-165,801 Reduced 3.13%	5,132,287 $153 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $134,790 - $202,228	8,569 Added 0.16%	5,298,088 $95.5 Million
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $5.13 Million - $7.07 Million	-335,225 Reduced 5.96%	5,289,519 $84.9 Million
Q4 2022 Feb 14, 2023	SELL	$15.49 - $19.05 $111,744 - $137,426	-7,214 Reduced 0.13%	5,624,744 $103 Million
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $2.85 Million - $3.52 Million	157,499 Added 2.88%	5,631,958 $111 Million
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $8.75 Million - $14.7 Million	530,446 Added 10.73%	5,474,459 $102 Million
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $2.58 Million - $4.26 Million	150,375 Added 3.14%	4,944,013 $109 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $34.7 Million - $51 Million	1,795,126 Added 59.87%	4,793,638 $136 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $4.91 Million - $7.33 Million	290,687 Added 10.74%	2,998,512 $63.1 Million
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $11.2 Million - $14.9 Million	704,137 Added 35.14%	2,707,825 $51 Million
Q1 2021 May 17, 2021	BUY	$13.3 - $17.55 $7.31 Million - $9.65 Million	549,722 Added 37.81%	2,003,688 $30.6 Million
Q4 2020 Feb 16, 2021	BUY	$12.08 - $17.46 $7 Million - $10.1 Million	579,124 Added 66.2%	1,453,966 $20.5 Million
Q3 2020 Nov 16, 2020	SELL	$13.62 - $17.66 $162,350 - $210,507	-11,920 Reduced 1.34%	874,842 $13.7 Million
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $11.6 Million - $20.6 Million	886,762 New	886,762 $15.5 Million

Others Institutions Holding CRNX

# of Institutions

254

Shares Held

89.2M

Call Options Held

26.1K

Put Options Held

11.8K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $1.98B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.

Account

Driehaus Capital Management LLC Crinetics Pharmaceuticals, Inc. Transaction History